Quick Overview
- Moderna shares plummeted 10.7% on July 10, 2026, shedding $8.17 to settle at $68.39
- Company executives offloaded $6.2 million in shares over the previous three months without any insider purchases
- First quarter earnings per share registered at -$3.40, falling short of the -$3.02 projection, while revenue reached $389M, surpassing the $236.37M estimate
- Analyst consensus points to a “Reduce” recommendation with an average price objective of $38.27
- QRG Capital Management initiated a stake, acquiring 13,666 shares valued at approximately $694,000
The biotech company experienced a brutal trading session on July 10, 2026, with shares collapsing 10.7% ā an $8.17 decline ā to finish at $68.39. This downturn continues a troubling trajectory for the vaccine manufacturer.
Trading commenced that session at $76.56. The biotechnology firm’s 52-week trading range spans from $22.28 to $85.60, positioning the current valuation in the upper portion of that spectrum ā though the recent descent indicates momentum may be shifting.
The company’s latest quarterly disclosure, unveiled May 1, offered little encouragement to shareholders. Moderna recorded a quarterly deficit of $3.40 per share, underperforming the analyst projection of -$3.02. This shortfall represents the kind of disappointment that lingers in investor memory.
Topline results painted a brighter picture. The biotechnology firm generated $389 million in quarterly revenue, substantially exceeding the Wall Street consensus of $236.37 million. This represents a year-over-year surge of 260.2%.
However, strong revenue growth offers limited comfort when the bottom line remains deeply negative. The company operates with a net margin of negative 143.55% and records a return on equity of negative 26.64%.
Executive Stock Sales Raise Eyebrows
Company leadership has been actively reducing their holdings. Throughout the preceding three-month period, executives disposed of $6.2 million in equity ā with zero purchases recorded.
Board member Noubar Afeyan offloaded 9,263 shares on May 21 at an average transaction price of $46.84, reducing his stake by 70.24%. Chief Executive Stephen Hoge divested 53,336 shares on June 15 at $51.37 each, a sale totaling approximately $2.74 million.
While these transactions occurred through predetermined 10b5-1 trading arrangements, the magnitude of executive selling rarely goes unnoticed by market participants.
Company insiders maintain 10.80% ownership. Institutional stakeholders control 75.33%.
Analyst Community Remains Skeptical
Street sentiment offers little optimism at present. Among the 18 research analysts tracking Moderna, two assign Buy ratings, eleven recommend Hold, and five advocate Sell. The weighted average translates to a “Reduce” rating.
The mean price objective stands at $38.27 ā significantly beneath current trading levels.
Morgan Stanley recently adjusted its price objective upward from $33 to $39 while maintaining an “equal weight” stance. Goldman Sachs elevated its target from $43 to $49 with a “neutral” rating. Bank of America increased its objective from $34 to $38 while preserving an “underperform” designation.
Weiss Ratings sustained a “sell (d-)” recommendation on June 12.
Regarding institutional activity, QRG Capital Management established a fresh position during Q1, accumulating 13,666 shares valued at roughly $694,000. Several other smaller investment firms also added holdings, though the quantities remained relatively minor.
Moderna’s GF Score registers at 58 out of 100. Financial Strength earns 7/10, Growth scores 7/10, while Profitability languishes at merely 3/10.
The 50-day moving average stands at $55.75. The 200-day moving average rests at $49.53. Sell-side analysts collectively anticipate Moderna will report -$6.51 EPS for the complete fiscal year.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
